Loading...
•
Dec 31, 2023
Corcept Therapeutics Q4 2023 Earnings Report
Corcept Therapeutics reported a strong Q4 2023 with increased revenue and net income.
Key Takeaways
Corcept Therapeutics announced its Q4 2023 financial results, featuring a 31% increase in revenue compared to Q4 2022, and a notable rise in net income. The company reiterated its 2024 revenue guidance, reflecting confidence in continued growth and market trends.
Fourth quarter revenue increased by 31% to $135.4 million compared to the same period in 2022.
Full year 2023 revenue was $482.4 million, a 20% increase over 2022.
Net income for the fourth quarter was $31.4 million, up from $16.6 million in Q4 2022.
The company reiterated its 2024 revenue guidance of $600 – $630 million.
Forward Guidance
Corcept Therapeutics anticipates continued revenue growth and is focused on advancing its clinical development programs, with several important milestones expected this year.
Positive Outlook
- On-track to submit NDA for relacorilant in Cushing’s syndrome in Q2.
- Expecting results from trials in Cushing’s syndrome (GRACE, GRADIENT and CATALYST) this year.
- Expecting results from ovarian cancer (ROSELLA) trial by year-end.
- Expecting results from ALS (DAZALS) trial by year-end.
- CATALYST trial findings are expected to stimulate physicians' efforts to screen for hypercortisolism in patients with difficult-to-control diabetes.
Challenges Ahead
- Risks related to the development of relacorilant, dazucorilant, miricorilant and other product candidates.
- Potential impact of competing treatments for hypercortisolism, including generic versions of Korlym.
- Risks related to obtaining acceptable prices and adequate insurance coverage and reimbursement for Korlym.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...